Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Hofseth Biocare ASA Announces New Study Results


Friday, 20 Sep 2013 06:03am EDT 

Hofseth Biocare ASA announced that the study on the effects of HBCs salmon oil shows that using HBCs fresh salmon oil (OmeGo) has a superior performance compared to other fish oils. Circulating levels of oxidized low density lipoprotein Beta2-glycoprotein I complex (oxLDL-GP) have been previously correlated with adverse cardio-vascular events. This study measured the effect of consuming various dietary oil capsules on oxLDL-GP serum concentrations in healthy human subjects. The dietary oil capsules tested were enzymatically liberated salmon oil, as a proxy for the entire lipid soluble fraction of whole salmon, high DHA algae oil and standard 18/12 fish oil. The results showed that only the enzymatically liberated salmon oil had a significant lowering of circulating serum concentration ofoxLDL-GP, after three weeks of treatment. This result lends support to the developing theory, that eating whole functional foods for their nutritive and health benefiting effects may not be reproduced by highly-refined supplements derived from these foods.